The most consistent evidence for increased cancer risk among people with IBD exists for those treated with thiopurine medications (at risk for lymphoma [14,15,16], and non-melanoma skin cancer [17,18,19,20]), and among those treated with anti-tumor necrosis factor (anti-TNF) biological therapy (at risk for melanoma [21]). This evidence concerns the gene TNF and melanoma.